China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. develops, manufactures, and sells traditional Chinese medicine pieces and related pharmaceutical products in China. The company serves hospitals, pharmaceutical wholesalers, pharmacies, and other healthcare distributors through a sales network centered in Jiangsu and other provinces in China.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaProcessed TCMP products supplied for hospital and pharmacy use.
Sales of TCMPs and related products through wholesale distribution channels.
Sales of unprocessed medicinal materials used in Chinese medicine supply chains.
Smaller product lines and miscellaneous pharmaceutical-related revenue.
Tuotteet
Raportoitu · osuus liikevaihdosta- Revenues From Third Parties99,8 %
- Revenue From Related Parties0,2 %
Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells primarily to hospitals, especially traditional Chinese medicine hospitals, and to pharmaceutical wholesalers that redistribute products into healthcare channels. Its end-customer base also includes chain pharmacies and other pharmaceutical companies across several provinces in China.
Buy TCMP products for direct patient treatment and hospital formularies.
Purchase products for redistribution to hospitals and healthcare distributors.
Buy packaged Chinese medicine products for retail and dispensing.
Purchase raw materials or related products for downstream pharmaceutical use.
Source products to reach hospitals and local medical channels.
Strategia
The company is focused on expanding and modernizing its TCMP portfolio through research and development, including advanced non-decocting products. It also emphasizes direct distributor relationships and a relatively low-intermediary sales model to support channel efficiency and product reach across China.
New formulations and processing methods help differentiate the product portfolio and support demand from hospitals and pharmacies.
Broader provincial coverage improves customer access and supports sales growth in fragmented Chinese healthcare markets.
Better production control and quality benchmarking are important in regulated TCMP markets and for hospital acceptance.
Maantiede
The company is based in Taizhou, Jiangsu, China, and its commercial activity is concentrated in Chinese provincial markets. Its sales offices cover 12 major provinces and municipalities, with reported end-customers in Jiangsu, Anhui, Jiangxi, Guangdong, Hubei and other regions, making domestic China the core operating geography.
Riskit
The business depends on regulatory acceptance, customer relationships, and the continued adoption of TCMP products in hospitals and pharmacies. It also faces concentration risk in China, execution risk in distributor-led sales, and accounting complexity tied to credit losses, inventory, and fair value estimates.
- China market concentrationVaikutus: KorkeaTodennäköisyys: Korkea
Sales, customers, and operations are concentrated in Chinese provinces, so domestic policy or demand changes would affect the business directly.
Kohdistuu: Domestic pharmaceutical and hospital channels in China
- Customer concentration in hospitals and wholesalersVaikutus: KorkeaTodennäköisyys: Korkea
A large share of revenue depends on a limited set of institutional buyers and distributor relationships.
Kohdistuu - Regulatory and product approval riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Some new products may require regulatory approval, and pharmaceutical standards can affect launch timing and commercialization.
Kohdistuu: TCMP development and new product introductions
- Credit risk on distributor and customer receivablesVaikutus: KeskitasoTodennäköisyys: Kohtalainen
A wholesaler-heavy model can delay collection and create exposure to doubtful accounts.
Kohdistuu: Trade receivables and channel partners
- Inventory and capacity riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Pharmaceutical preparation and raw material production can leave the company exposed to inventory obsolescence and abnormal capacity issues.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätReceivables from wholesalers and distributors require judgment about collectability.
Vaikutus: Can change bad debt expense and net assets
Production and raw material inventories may be affected by abnormal capacity and obsolescence assumptions.
Vaikutus: Can alter cost of revenues and gross profit
Revenue recognition depends on estimated return rates in the distribution channel.
Vaikutus: Can affect net revenue and quarterly comparability
Fair value measurements can create volatility in liabilities and earnings.
Vaikutus: Can materially affect reported gains or losses
Long-lived assets and ROU assets require periodic recoverability assessments.
Vaikutus: Can lead to non-cash impairment charges
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
China Pharma Holdings, Inc
CPHI · Pharmaceutical Preparations
Universe Pharmaceuticals INC
UPC · Pharmaceutical Preparations
Universe Pharmaceuticals INC is a Cayman Islands holding company headquartered in Ji'an, Jiangxi, China, that operates through subsidiaries in Hong Kong and mainland China.
Longduoduo Co Ltd
LDDD · Services-Health Services
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct…
Concord Medical Services Holdings Ltd
CCM · Services-Offices & Clinics of Doctors of Medicine
Concord Medical Services Holdings Ltd is a medical services group headquartered in Beijing, with operations centered on hospital, clinic, and other healthcare service assets in China.
111, Inc.
YI · Retail-Drug Stores and Proprietary Stores
HUTCHMED (China) Ltd
HCM · Pharmaceutical Preparations
HUTCHMED (China) Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.
Päivitetty: 28.9.2026